Adma Biologics was downgraded to 'Neutral' by Cantor Fitzgerald, which cited poor investor communication after a short report by Culper Research. Analysts expressed concern over the lack of specific feedback addressing the claims, as well as rising days sales outstanding and accounts receivable. ADMA stock has dropped nearly 29% since the report.